History

2003-2005: Organisation and structuring

2003 Creation of the Novacap group, Bain Capital is the group’s majority shareholder

2004 Launch of a new sodium bicarbonate unit

2006-2011: Organic development improvement

2006 Launch of the calcium chloride unit in Pont-de-Claix

2008 Launch of the second sodium bicarbonate unit

2010 Launch of the Isopropanol unit in Roussillon

2011 Ardian acquires 96% of Novacap

 

 

 

2011-2016: Growth acceleration and internationalisation

2011 Start-up of the third sodium bicarbonate unit

2011 Acquisition of Novacyl, worldwilde leader in  Aspirin, salicylic acid and its derivated

2011 Launch of a new ferric chloride production unit in Pont-de-Claix (France)

2012 Capacity increase on alpha methyl styrene

2013 Acquisition of a majority stake (51%)  in Yangzi Pharmaceutical Chemical in China

2014 Launch of homosalate and sodium silicates.

2014 Acquisition of a 51% majority stake in Puyuan .

2015 Acquisition of Uetikon a German-based APIs and fine chemicals manufacturer.

2015 Novacap enters into a partnership with the innovative biotechnology startup Alganelle, specialised in the development and production of high added-value molecules, derived from microalgae.

2016 EURAZEO becomes the majority shareholder of the group alongside MERIEUX development, ARDIAN and the management team.

 

 

Since 2016 : Strengthening the technological and products offering for the pharmaceutical, cosmetics and fine chemistry markets.

 

2017 Novacap acquires 96.5% of Puyuan

2017 Novacap acquires 77.57% of Yangzi Pharmaceutical Chemical

April 2017 Novacap announced a project of strategic combination with PCAS, specialising in the development and production of complex molecules for life sciences and innovative technologies, through a sale of blocks of shares followed by a tender offer.

April 2017 Launch of a new production unit for manufacturing DIPE (Diisopropyl Ether) on the Roussillon chemical platform.

May 2017 Novacap acquires ID bio, a manufacturer of botanical ingredients and H2B, a manufacturer of ingredients for in-vitro diagnosis.

May 2017 Novacap acquires PCAS, specializes in the development and production of complex molecules for life sciences and innovative technologies (cDMO).

July 2017 Acquisition of a majority stake in Chemoxy International Ltd, a leading contract manufacturer for specialty chemicals and environmentally-friendly solvents.

December 2017 Novacap supports Harmonic Pharma, an innovative company specialized in Polypharmacology through a capital increase.

June 2018 Novacap acquires PCI Synthesis, a leading U.S. pharmaceutical contract development and manufacturing organization (CDMO),